AU Patent

AU2021269374B2 — Use of cannabinoids in the treatment of epilepsy

Assigned to Jazz Pharmaceuticals Research UK Ltd · Expires 2023-12-14 · 2y expired

What this patent protects

The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. 5 CBD appears particularly effective in reducing focal seizures in patients suffering …

USPTO Abstract

The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. 5 CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, 10 focal seizures with impairment.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021269374B2
Jurisdiction
AU
Classification
—
Expires
2023-12-14
Drug substance claim
No
Drug product claim
No
Assignee
Jazz Pharmaceuticals Research UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.